Online inquiry

IVTScrip™ mRNA-Anti-Factor IX substitute, CB 2679d(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ5220MR)

This product GTTS-WQ5220MR is a type of mRNA modified with N1-Methylpseudo-UTP, which ecodes the monoclonal antibody that targets Factor IX substitute gene. The antibody can be applied in Hemophilia B research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000133.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2158
UniProt ID P00740
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-Factor IX substitute, CB 2679d(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ5220MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ3136MR IVTScrip™ mRNA-Anti-C3&C4, APT070(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA APT070
GTTS-WQ12284MR IVTScrip™ mRNA-Anti-CD274, MSB-0010718C(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MSB-0010718C
GTTS-WQ9003MR IVTScrip™ mRNA-Anti-IL13, IMA-638(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA IMA-638
GTTS-WQ4017MR IVTScrip™ mRNA-Anti-PDCD1, BGB-A317(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BGB-A317
GTTS-WQ12716MR IVTScrip™ mRNA-Anti-DLL4&VEGFA, OMP-305B83(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA OMP-305B83
GTTS-WQ4475MR IVTScrip™ mRNA-Anti-CD28, BMS-931699(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BMS-931699
GTTS-WQ2538MR IVTScrip™ mRNA-Anti-GCGR, AMG 477(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA AMG 477
GTTS-WQ2393MR IVTScrip™ mRNA-Anti-CD3E&EPCAM, AMG 110(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA AMG 110
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW